Cited 28 times in
Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신상준 | - |
dc.contributor.author | 정민규 | - |
dc.date.accessioned | 2017-11-02T08:07:37Z | - |
dc.date.available | 2017-11-02T08:07:37Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154108 | - |
dc.description.abstract | PURPOSE: Ipilimumab improves survival in advanced melanoma patients. However, the efficacy and safety of ipilimumab has not been evaluated in Asian melanoma patients with a high frequency of mucosal and acral melanoma subtypes. MATERIALS AND METHODS: Advanced melanoma patients treated with 3 mg/kg ipilimumab in a Korean multicenter named-patient program (NPP) were evaluated between September 2014 and July 2015. Baseline characteristics and blood parameters including neutrophil to lymphocyte ratio (NLR) were assessed, and outcome and adverse events were evaluated according to subtypes. RESULTS: A total of 104 advanced melanoma patients were treated. The primary sites were acral (31.7%), mucosal (26%), cutaneous (26%), uveal (9.6%), and unknown (6.7%). Sixty-eight patients (65.4%) experienced adverse events, and the most common toxicity was skin rash (22.1%), 10 patients (9.6%) experienced adverse events of grade 3 or higher. The median progression-free survival (PFS) was 2.73 months (95% confidence interval, 2.67 to 2.85), and there was no difference in PFS according to subtypes. Poor performance status, liver metastasis, and NLR (≥ 5) were independent poor prognostic factors by multivariate analysis. CONCLUSION: In the Korean NPP cohort, ipilimumab showed similar efficacy and tolerability compared to Western patients, regardless of subtypes. All subtypes should benefit from ipilimumab with consideration of performance status, liver metastasis, and NLR. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents, Immunological/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents, Immunological/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents, Immunological/therapeutic use* | - |
dc.subject.MESH | Biomarkers | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Ipilimumab/administration & dosage | - |
dc.subject.MESH | Ipilimumab/adverse effects | - |
dc.subject.MESH | Ipilimumab/therapeutic use* | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Melanoma/diagnosis | - |
dc.subject.MESH | Melanoma/drug therapy* | - |
dc.subject.MESH | Melanoma/mortality | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Molecular Targeted Therapy | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort | - |
dc.type | Article | - |
dc.publisher.location | Korea | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Minkyu Jung | - |
dc.contributor.googleauthor | Jeeyun Lee | - |
dc.contributor.googleauthor | Tae Min Kim | - |
dc.contributor.googleauthor | Dae Ho Lee | - |
dc.contributor.googleauthor | Jin Hyung Kang | - |
dc.contributor.googleauthor | Sung Young Oh | - |
dc.contributor.googleauthor | Soo Jung Lee | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.identifier.doi | 10.4143/crt.2016.024 | - |
dc.contributor.localId | A03606 | - |
dc.contributor.localId | A02105 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.relation.journalsince | 2001~ | - |
dc.identifier.pmid | 27121719 | - |
dc.relation.journalbefore | ~2001 Journal of the Korean Cancer Research Association (대한암학회지) | - |
dc.subject.keyword | Biomarkers | - |
dc.subject.keyword | Immunotherapy | - |
dc.subject.keyword | Ipilimumab | - |
dc.subject.keyword | Melanoma | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Jung, Min Kyu | - |
dc.contributor.affiliatedAuthor | Jung, Min Kyu | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.citation.title | Cancer Research and Treatment | - |
dc.citation.volume | 49 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 44 | - |
dc.citation.endPage | 53 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.49(1) : 44-53, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 41604 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.